About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Blood cancers are far too common, comprising almost 10% of new cancer diagnoses each year in the U.S. Almost every 10 minutes, an American succumbs to a blood cancer. Unfortunately, many of these are children.
That's why the Weizmann Institute of Science’s researchers are conducting innovative studies and taking novel approaches to blood cancers. September is Blood Cancer Awareness Month, and we’d like to share with you some of Weizmann’s current investigations.
September 2020
The Jerusalem Post reports on a technology, developed by Prof. Ido Amit and team, that reveals the inner functions of cells. This could lead to new cancer immunotherapies.
August 14, 2020
REHOVOT, ISRAEL—July 16, 2020—Choosing the right drug for each cancer patient is key to successful treatment, but physicians currently have few reliable pointers to guide them in designing treatment protocols. Researchers at the Weizmann Institute of Science and the Broad Institute of MIT and Harvard have now developed a new method...
July 16, 2020
REHOVOT, ISRAEL—June 2, 2020—Cancer cells are comfy havens for bacteria. That conclusion arises from a rigorous study of over 1,000 tumor samples of different human cancers.
June 02, 2020
Covering the recent breakthrough by Dr. Ravid Straussman, New Scientist says that the “first comprehensive survey of the microorganisms that live inside tumours has found that bacteria reside in those from many different cancer types.”
May 28, 2020
May is Skin Cancer Awareness Month, and Israel21C reports on research advances – including by Prof. Yardena Samuels.
May 14, 2020
REHOVOT, ISRAEL—February 18, 2020—One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.
February 18, 2020
A new cancer therapy gives us all hope. This latest breakthrough combines photo-dynamic therapy using laser light with a novel drug to treat early-stage prostate cancer. The combination makes it possible to safely treat cancerous tissue using a minimally invasive procedure, with none of the side effects of surgery or radiation.
Acute myeloid leukemia (AML), a cancer of the blood and bone marrow, is usually only diagnosed at an advanced stage, at which point it requires aggressive treatment. Although AML is a relatively rare disease, accounting for just 1.8 percent of cancer deaths in the U.S., its incidence is expected to increase as the population ages. The average age of diagnosis is 68.
©2020 American Committee for the Weizmann Institute of Science